EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study

Alessandra Oliva, L Liguori, S Covino, F Petrucci, F Cogliati-Dezza, A Curtolo, G Savelloni, M Comi, F Sacco, G Ceccarelli, A Viscido, F Alessandri und 4 weitere

European Journal of Clinical Microbiology & Infectious Diseases · 2024

DOI: 10.1007/s10096-024-04833-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Alessandra Oliva und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy. alessandra.oliva@uniroma1…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We assessed the clinical effectiveness of cefiderocol (CFDC) in comparison with colistin (COL) for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections (BSI). Materials/methods Retrospective cohort study including adults with CRAB-BSI. Outcomes were mortality, clinical cure and adverse events during therapy. The average treatment effect of CFDC compared to COL was weighted with the inverse-probability treatment weight (IPTW).

Results

Overall, 104 patients were included (50 CFDC, 54 COL), median age 66.5 years, median Charlson Comorbidity Index 5, septic shock in 33.6% of patients. Primary BSI accounted for 43.3% of cases, followed by ventilator-associated pneumonia (VAP) (26%), catheter-related BSI (20.2%) and hospital-acquired pneumonia (HAP) (9.6%). Although not significantly, mortality at all time points was lower for CFDC than COL, while clinical cure was higher in CFDC than COL (66% vs. 44.4%, p = 0.027). Adverse events were more frequent in COL than CFDC-group (38.8% vs. 10%, p < 0.0001), primarily attributed to acute kidney injury (AKI) in the COL group. Patients with bacteremic HAP/VAP treated with CFDC had a significant lower 30-d mortality and higher clinical cure than COL ( p = 0.008 and p = 0.0008, respectively). Increment of CCI ( p = 0.005), ICU ( p = 0.025), SARS-CoV2 ( p = 0.006) and ECMO ( p < 0.0001) were independently associated with 30-d mortality, while receiving CFDC was not associated with survival.

Conclusions

CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsCarbapenemsBacteremiaCefiderocolCOVID-19HumansAgedMaleFemaleRetrospective StudiesMiddle AgedTreatment OutcomeColistinCephalosporinsSARS-CoV-2Aged, 80 and overPneumonia, Ventilator-Associated

Stichwörter der Autor:innen

Bloodstream infectionCarbapenem-resistant Acinetobacter baumanniiCefiderocolColistinPneumoniaVentilator-acquired pneumonia

Substanzen

Anti-Bacterial AgentsCarbapenemsCefiderocolColistinCephalosporins

Autor:innen und Institutionen

  • Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy. alessandra.oliva@uniroma1.it.
  • Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy.
  • Microbiology and Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Department of General and Specialistic Surgery, Sapienza University of Rome, Rome, Italy.

Förderung

  • Università degli Studi di Roma La Sapienza

Zitieren

APA

Oliva, A., Liguori, L., Covino, S., Petrucci, F., Cogliati-Dezza, F., Curtolo, A., Savelloni, G., Comi, M., Sacco, F., Ceccarelli, G., Viscido, A., Alessandri, F., Raponi, G., Pugliese, F., Mastroianni, C. M., & Venditti, M. (2024). Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04833-8

Vancouver

Oliva A, Liguori L, Covino S, Petrucci F, Cogliati-Dezza F, Curtolo A, et al. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04833-8

BibTeX
@article{Oliva2024,
  author = {Oliva, Alessandra and Liguori, L and Covino, S and Petrucci, F and Cogliati-Dezza, F and Curtolo, A and Savelloni, G and Comi, M and Sacco, F and Ceccarelli, G and Viscido, A and Alessandri, F and Raponi, G and Pugliese, F and Mastroianni, C M and Venditti, M},
  title = {Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  doi = {10.1007/s10096-024-04833-8}
}
Kostenlos starten →